Current treatment for chronic arthritis in childhood

Current Opinion in Pediatrics

Volumn 14, Issue 6, 2002, Pages 684-687

  Cron, Randy Q ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MELOXICAM; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; THALIDOMIDE; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC PNEUMONITIS; CHILD; CHILDHOOD DISEASE; CHRONIC ARTHRITIS; CLINICAL TRIAL; COXITIS; DISEASE ACTIVITY; DISEASE CONTROL; DRUG INDUCED DISEASE; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; LYMPHOMA; PRIORITY JOURNAL; PSEUDOPORPHYRIA; REVIEW; SCAR FORMATION; SIDE EFFECT; TREATMENT INDICATION;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHRONIC DISEASE; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036889589     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200212000-00006     Document Type: Review

References (39)

1. Petty RE: Growing pains: The ILAR classification of juvenile idiopathic arthritis. J Rheumatol 2001, 28:927-928.
2. Minden K, Niewerth M, Listing J, et al.: Health care provision in pediatric rheumatology in Germany-national rheumatologic database. J Rheumatol 2002, 29:622-628.
3. Cron RQ, Sharma S, Sherry DD: Current treatment by United States and Canadian pediatric rheumatologists. J Rheumatol 1999, 26:2036-2038. A large survey of North American pediatric rheumatologists analyzing specific treatment practices for common childhood rheumatic disease including the chronic juvenile arthritides by subtype.
4. Brunner HI, Kim KN, Ballinger SH, et al.: Current medication choices in juvenile rheumatoid arthritis II-update of a survey performed in 1993. J Clin Rheumatol 2001, 7:295-300.
5. Foeldvari I, Burgos-Vargas R, Thon A, et al.: High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. J Rheumatol 2002, 29(5):1079-1083. The first report of a trial studying a relatively selective COX-2 inhibitor to treat children with JRA. Meloxicam suspension was felt to be safe and effective.
6. De Silva B, Banney L, Uttley W, et al.: Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis. Pediatr Dermatol 2000, 17:480-483.
7. Cron RQ, Finkel TH: Nabumetone induced pseudoporphyria in childhood. J Rheumatol 2000, 27:1817-1818.
8. Cummins R, Wagner-Weiner L, Paller A: Pseudoporphyria induced by celecoxib in a patient with juvenile rheumatoid arthritis. J Rheumatol 2000, 27:2938-2940.
9. Sherry DD, Stein LD, Reed AM, et al.: Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999, 42:2330-2334. A comparison analysis of children with pauciarticular JRA who were or were not treated with intraarticular corticosteroid injections. This is one of the first studies to document an objective advantage from the use of intraarticular corticosteroid injections in JRA.
10. Neidel J, Boehnke M, Kuster RM: The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis. Arthritis Rheum 2002, 46:1620-1628.
11. Brooks CD: Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol 2001, 28:845-853.
12. Woo P, Southwood TR, Prieur AM, et al.: Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000, 43:1849-1857. A well-conducted trial demonstrating the benefit of MTX in the treatment of extended oligoarticular (polyarticular course) and systemic-onset JIA.
13. Weiss AH, Wallace CA, Sherry DD: Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998, 133:266-268.
14. Hashkes PJ, Balistreri WF, Bove KE, et al.: The relation of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1999, 134:47-52. A study of 33 liver biopsies from 25 patients with JRA who had been treated with long-term MTX. No significant fibrosis was seen on any of the biopsies. However, body mass index and elevated serum liver enzymes correlated with mild liver abnormalities on biopsy.
15. Cron RQ, Sherry DD, Wallace CA: Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr 1998, 132:901-902.
16. Muzaffer MA, Schneider R, Cameron BJ, et al.: Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1996, 128:698-700.
17. Savolainen HA, Leirisalo-Repo M: Eosinophilia as a side-effect of methotrexate in patients with chronic arthritis. Clin Rheumatol 2001, 20:432-434.
18. Ravelli A, Caria MC, Buratti S, et al.: Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2001, 28:865-867.
19. Padeh S, Sharon N, Schiby G, et al.: Hodgkin's lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 1997, 24:2035-2037.
20. Londino AV Jr, Blatt J, Knisely AS: Hodgkin's disease in a patient with juvenile rheumatoid arthritis taking weekly low dose methotrexate. J Rheumatol 1998, 25:1245-1246.
21. Cleary AG, McDowell H, Sills JA: Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma. Arch Dis Child 2002, 86:47-49.
22. Wallace CA: Methotrexate: More questions than answers. J Rheumatol 2000, 27:1834-1835.
23. Lovell DJ, Giannini EH, Reiff A, et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000, 342:763-769. A randomized, double-blind study of 69 patients with polyarticular JRA demonstrated that TNF inhibition led to significant improvement in arthritis and was well tolerated.
24. Billiau AD, Cornillie F, Wouters C: Infliximab for systemic onset juvenile idiopathic arthritis: Experience in 3 children. J Rheumatol 2002, 29:1111-1114.
25. Kietz DA, Pepmueller PH, Moore TL: Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002, 61:171-173.
26. Schmeling H, Mathony K, John V, et al.: A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: A pilot study. Ann Rheum Dis 2001, 60:410-412.
27. Takei S, Groh D, Bernstein B, et al.: Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol 2001, 28:1677-1680.
28. Reiff A, Takei S, Sadeghi S, et al.: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44:1411-1415. A small prospective study demonstrated that TNF inhibition was beneficial to a subset of children with chronic anterior uveitis that had been previously failed topical steroids, MTX, and cyclosporin A.
29. Prahalad S, Bove KE, Dickens D, et al.: Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001, 28:2120-2124.
30. Cassidy JT: Medical management of children with juvenile rheumatoid arthritis. Drugs 1999, 58:831-850. A thorough review of the medical management of JRA up through 1999.
31. Kimura Y, Fieldston E, Devries-Vandervlugt B, et al.: High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis. J Rheumatol 2000, 27:2018-2024.
32. Gerloni V, Cimaz R, Gattinara M, et al.: Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) 2001, 40:907-913. A prospective trial evaluating the use of cyclosporin A in the treatment of 34 children with systemic-onset JIA. Of the study population, 66% withdrew from the study because of side effects or inefficacy. Cyclosporin A was useful for some patients to lower the systemic corticosteroid dose and to control the fever.
33. Stephan JL, Kone-Paut I, Galambrun C, et al.: Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 2001, 40:1285-1292.
34. Wallace CA, Sherry DD: Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997, 40:1852-1855.
35. Lehman TJ, Striegel KH, Onel KB: Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr 2002, 140:125-127.
36. Barron KS, Wallace C, Woolfrey CEA, et al. Autologous stem cell transplantation for pediatric rheumatic diseases. J Rheumatol 2001, 28:2337-2358. A well-organized summary of the National Institutes of Health workshop on protocol development for autologous stem cell transplantation for pediatric rheumatic diseases. This includes the experience of bone marrow transplantation for pediatric rheumatic diseases up to the date of the workshop in June 2000.
37. Sherry DD: What's new in the diagnosis and treatment of juvenile rheumatoid arthritis. J Pediatr Orthop 2000, 20:419-420.
38. Arkachaisri T, Lehman TJ: Use of biologics in the treatment of childhood rheumatic diseases. Curr Rheumatol Rep 2000, 2:330-336. An excellent summary of biologic therapy currently available and under consideration for use in the treatment of pediatric rheumatic diseases.
39. Ilowite NT: Current treatment of juvenile rheumatoid arthritis. Pediatrics 2002, 109:109-115. A well written, up-to-date summary of current therapy for JRA organized by individual drugs.